Burosumab treatment for X-linked hypophosphataemia may begin in the first year of life, suggest phase 2 trial findings published in The Lancet Diabetes & Endocrinology.
The UK Achondroplasia Network has developed consensus guidelines on multidisciplinary care of children and young people with achondroplasia from diagnosis until adulthood.
Children with osteogenesis imperfecta are more likely to use anti-fracture drugs than their older counterparts, but underuse is common across all age groups, US study findings indicate.
More than a quarter of childhood cancer survivors have moderate or severe bone mineral density deficits in adulthood, report US researchers who believe targeted interventions could reduce this burden.
Children and young adults with congenital adrenal hyperplasia may be at long-term risk of low bone mineral density, with the greatest risk found in boys and young men, Italian researchers have found.
Once daily oral treatment with infigratinib has a tolerable side effect profile and a significant positive benefit on both annualised height velocity and upper-to-lower body segment ratio in children with achondroplasia, indicates research published in The New England Journal of Medicine.
Vosoritide treatment appears to increase growth velocity in children with hypochondroplasia and is well tolerated, show study findings
Primary care electronic health record codes for rickets, genu varum or low levels of phosphate could help flag a potential diagnosis of X-linked hypophosphataemia, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.
Vosoritide may be given to children with achondroplasia aged under 60 months after phase 2 trial findings point to a tolerable adverse event profile and an increase in height Z score compared with placebo.
Why is the growth plate the most important organ for childhood growth: how can it be investigated for clinical diagnosis?
